Join us in-person for the 2025 DTRF "Together We Will" Weekend in Chicago from Sept. 12-13! - Register Today

Gerlinde Wernig, MD, Stanford School of Medicine, Department of Pathology

“Studying CD47 blockade as an immunotherapy for desmoid-type fibromatosis.” Year 1 of 2

Jointly funded by the DTRF and Desmoid Tumour Foundation of Canada (DFC)